Lumira Ventures' Fund V First Close: $200 Million, a New Managing Partner, and a Smaller Target Than Fund IV

$200 million is the target size of Lumira Ventures' fifth fund, which announced its first close on April 20, 2026 — alongside a leadership transition and a target slightly below its 2021 predecessor.

Lumira Ventures has spent more than two decades backing biotech and medical-device companies out of Toronto, and its first-close announcement for Fund V landed at a moment when the broader healthcare venture market split sharply between a handful of billion-dollar mega-funds and everyone else. Here is what Fund V actually is, why its target sits below the firm's own prior fund, and how it compares to the healthcare VC funds that raised far more capital around the same time.

Lumira Ventures Fund V: What the First Close Actually Raised

Lumira Ventures announced the first closing of Lumira Ventures V, LP on April 20, 2026, without disclosing the specific first-close dollar amount. The fund's stated target final size is US$200 million (C$275 million), aimed at building biotechnology and medical technology companies across North America, with an explicit emphasis on markets outside traditional venture hubs like Boston and the Bay Area.

Fund V has already made its first investment: a US$52 million Series B round for a pre-commercial-stage medical device company that Lumira has not named publicly, according to the Fonds de solidarité FTQ's own press release announcing its participation as a limited partner. Northleaf Capital Partners is Fund V's anchor investor, returning from prior Lumira vehicles, and Fonds de solidarité FTQ — a Quebec labor-sponsored fund — has been an LP since the firm's founding, according to that same release.

A Leadership Transition Lands Alongside the Fundraise

Fund V's launch came with a change at the top: co-founder Gerry Brunk was named Managing Partner, while Peter van der Velden — previously the firm's lead partner — moved into a newly created Executive Chairman role, per the Fonds FTQ release and matching coverage from Yahoo Finance. Leadership transitions timed to a new fund close are common in venture — LPs generally want continuity in a firm's investment thesis while getting reassurance that a succession plan exists — and Lumira frames the move as building on, rather than departing from, the firm's existing strategy.

The firm's own materials tie the transition to a track record it wants LPs to underwrite for another fund cycle: more than 25 exits through IPOs and strategic acquisitions, and more than 40 regulatory approvals across its portfolio companies over its multi-decade history. Those are cumulative, all-time figures rather than a per-fund metric, so they say more about Lumira's longevity than about how Fund IV specifically performed — a distinction the announcement does not spell out.

Why Fund V's Target Sits Below Fund IV's Final Close

The detail most healthcare-VC coverage of this raise has skipped: Fund V's $200 million target is smaller than Fund IV's actual final close. Lumira Ventures IV closed at US$220 million (C$276 million) in 2021, which Private Capital Journal reported at the time was the largest institutional life sciences venture fund ever raised in Canada. A follow-on fund targeting less than its predecessor's final size is unusual in venture capital, where the norm is to step up fund size as a firm's track record and reputation grow.

Lumira's $200 Million vs. the Healthcare VC Mega-Funds of 2025-2026

Lumira's Fund V is raising into a healthcare venture market that grew sharply in aggregate — biotech companies banked more than $9.1 billion in the first half of 2026 alone, the strongest first-half total since 2022, according to BioPharma Dive's reporting. But that growth has concentrated disproportionately in a small number of very large fund vehicles rather than spreading evenly across firms of Lumira's size.

Sources: BioPharma Dive reporting on Sofinnova, Deerfield, and Forbion fund closes (2024-2025); Private Capital Journal (Lumira Fund IV); Fonds de solidarité FTQ and Lumira Ventures (Fund V target).

What the Headline Misses

Lumira's own framing emphasizes 25-plus exits and 40-plus regulatory approvals, but those are all-time, cumulative numbers spanning the firm's full multi-decade history, not a scorecard for Fund IV specifically. Without Fund IV's own realized return figures — which the firm has not disclosed publicly — it's not possible to independently verify whether Fund IV's vintage justifies LPs re-upping at a similar size for Fund V, or whether the smaller target reflects a more cautious fundraising environment for mid-sized, non-U.S. healthcare funds specifically.

Second, about two-thirds of 2026's first-half biotech venture rounds went to companies that already had a drug candidate in human testing, according to BioPharma Dive's analysis — meaning capital concentrated in later-stage, de-risked assets even as headline funding totals grew. This likely means Lumira's stated focus on underserved markets and earlier-stage bets sits somewhat against the grain of where the broader 2026 healthcare VC market has actually been allocating capital, which could make sourcing and pricing Fund V's early deals either a contrarian advantage or a harder road, depending on execution.

The Bottom Line for Founders and LPs

For Canadian and North American healthcare founders outside the major U.S. venture hubs, Lumira's $200 million target and its first $52 million Series B check show the firm is still writing meaningful growth-stage checks despite its smaller scale relative to Forbion, Sofinnova, or Deerfield. Its stated preference for underserved geographies could make it a more attentive lead investor for companies that mega-funds overlook simply because the check size doesn't move their needle.

For LPs, the honest read is that Fund V's below-Fund-IV target is either a sign of deliberate discipline in a selective fundraising market, or a signal that demand for a firm Lumira's size came in softer than the 2021 vintage — the public materials don't disclose enough about Fund IV's realized performance to distinguish between the two. Northleaf Capital Partners and Fonds de solidarité FTQ's continued backing is a reasonable proxy for confidence from LPs with the most direct visibility into Lumira's track record, but it is not a substitute for published fund-level return data.